Researchers have used a deep-learning algorithm to detect lung cancer accurately from computed tomography scans. The results of the study indicate that artificial intelligence can outperform human evaluation of these scans. The condition is the leading cause of cancer-related death in the U.S., and early detection is crucial for both stopping the spread of tumors and improving patient outcomes. As an alternative to chest X-rays, healthcare professionals have recently been using computed tomography (CT) scans to screen for lung cancer. In fact, some scientists argue that CT scans are superior to X-rays for lung cancer detection, and research has shown that low-dose CT (LDCT) in particular has reduced lung cancer deaths by 20%.

UCLA researchers have developed an artificial intelligence system that could help pathologists read biopsies more accurately and to better detect and diagnose breast cancer. The new system, described in a study published today in JAMA Network Open, helps interpret medical images used to diagnose breast cancer that can be difficult for the human eye to classify, and it does so nearly as accurately or better as experienced pathologists. "It is critical to get a correct diagnosis from the beginning so that we can guide patients to the most effective treatments," said Dr. Joann Elmore, the study's senior author and a professor of medicine at the David Geffen School of Medicine at UCLA. A 2015 study led by Elmore found that pathologists often disagree on the interpretation of breast biopsies, which are performed on millions of women each year. That earlier research revealed that diagnostic errors occurred in about one out of every six women who had ductal carcinoma in situ (a noninvasive type of breast cancer), and that incorrect diagnoses were given in about half of the biopsy cases of breast atypia (abnormal cells that are associated with a higher risk for breast cancer).

Life sciences Artificial Intelligence products and services company, AIRA Matrix ("AIRA Matrix"), and microscope-based digital pathology platform Augmentiqs ("Augmentiqs"), announced the world's first pre-clinical deployment of deep-learning algorithms in an augmented reality microscope. The partnership between AIRA Matrix and Augmentiqs will allow pathologists to deploy deep-learning AI algorithms directly in their existing microscope. AIRA Matrix and Augmentiqs partnered together to deploy Artificial Intelligence ("AI") based pathology algorithms directly within the microscope. In this deployment, the deep learning solution for fatty liver and myopathy tissue samples highlighted and quantified the region of interest as the slide was on the microscope stage, with results presented in real-time to the pathologist as augmented reality within the microscope eyepiece. A Japanese organization sponsored the pre-clinical study, which took place at Integrated Laboratory Systems ("ILS"), a North Carolina Contract Research Organization.

Do you think we're gonna be replaced?

Description: A down-to-earth, shy but confident take on machine learning techniques that you can put to work today.

Students at the University of Alberta are getting hands-on experience with artificial intelligence with a new robotic arm. Donated to the university's department of computing science by Kindred AI, a Canadian-based artificial intelligence company, the use of the robotic arm in the classroom helps students get a sense of reinforcement learning. Reinforcement learning is a branch of artificial intelligence, says Rapum Mahmood, assistant professor at the U of A and former Kindred AI research lead. "In reinforcement learning, we study by letting the agent interact with the environment, so that it can take the right set of actions," said Mahmood. Usually, the study is done through computer simulations and board games but in real-world applications, a robotic arm is used.

This work provides a review of this literature. The motivation for this summary arose from our companion paper Ruf and W ang [2019]. There we continue th e discussions of this note; in particular, of potentially problematic data leakage when training ANNs to historic financial data. This paper is organised in the following way. Section 2 featu res Table 1, a summary of the literature that concerns the use of ANNs for nonparametric pricing (and hedging) of options. Section 3 provides a list of recommended papers from Table 1. Section 4 provides a n overview of related work where ANNs are applied in the context of option pricing and hedging, but not necessarily as nonparametric estimation tools. Section 5 briefly discusses various regularisation techniq ues used in the reviewed literature.

One of the key requirements for incorporating machine learning into the drug discovery process is complete reproducibility and traceability of the model building and evaluation process. With this in mind, we have developed an end-to-end modular and extensible software pipeline for building and sharing machine learning models that predict key pharma-relevant parameters. The ATOM Modeling PipeLine, or AMPL, extends the functionality of the open source library DeepChem and supports an array of machine learning and molecular featurization tools. We have benchmarked AMPL on a large collection of pharmaceutical datasets covering a wide range of parameters. As a result of these comprehensive experiments, we have found that physicochemical descriptors and deep learning-based graph representations significantly outperform traditional fingerprints in the characterization of molecular features. We have also found that dataset size is directly correlated to prediction performance, and that single-task deep learning models only outperform shallow learners if there is sufficient data. Likewise, dataset size has a direct impact on model predictivity, independent of comprehensive hyperparameter model tuning. Our findings point to the need for public dataset integration or multi-task/transfer learning approaches. Lastly, we found that uncertainty quantification (UQ) analysis may help identify model error; however, efficacy of UQ to filter predictions varies considerably between datasets and featurization/model types. AMPL is open source and available for download at http://github.com/ATOMconsortium/AMPL.

Event detection (ED), a sub-task of event extraction, involves identifying triggers and categorizing event mentions. Existing methods primarily rely upon supervised learning and require large-scale labeled event datasets which are unfortunately not readily available in many real-life applications. In this paper, we consider and reformulate the ED task with limited labeled data as a Few-Shot Learning problem. We propose a Dynamic-Memory-Based Prototypical Network (DMB-PN), which exploits Dynamic Memory Network (DMN) to not only learn better prototypes for event types, but also produce more robust sentence encodings for event mentions. Differing from vanilla prototypical networks simply computing event prototypes by averaging, which only consume event mentions once, our model is more robust and is capable of distilling contextual information from event mentions for multiple times due to the multi-hop mechanism of DMNs. The experiments show that DMB-PN not only deals with sample scarcity better than a series of baseline models but also performs more robustly when the variety of event types is relatively large and the instance quantity is extremely small.

In this paper, we present an effective deep prediction framework based on robust recurrent neural networks (RNNs) to predict the likely therapeutic classes of medications a patient is taking, given a sequence of diagnostic billing codes in their record. Accurately capturing the list of medications currently taken by a given patient is extremely challenging due to undefined errors and omissions. We present a general robust framework that explicitly models the possible contamination through overtime decay mechanism on the input billing codes and noise injection into the recurrent hidden states, respectively. By doing this, billing codes are reformulated into its temporal patterns with decay rates on each medical variable, and the hidden states of RNNs are regularised by random noises which serve as dropout to improved RNNs robustness towards data variability in terms of missing values and multiple errors. The proposed method is extensively evaluated on real health care data to demonstrate its effectiveness in suggesting medication orders from contaminated values.